LUMA Vision receives 22 million US dollars in financing
New hope for patients with heart problems: LUMA Vision receives funding for 4D navigation platform to support cardiologists and improved therapies.
Munich/Dublin - LUMA Vision, a company developing a four-dimensional (4D) cardiac imaging and navigation platform, announced that it has closed a $22 million Series A-3 financing. The financing round was led by existing investors including EQT LifeSciences, Atlantic Bridge University Fund and imec.xpand and also included an undisclosed international medical device company, Atlantic Bridge Growth and Bayern Kapital as new investors. The funds are intended to drive the further development of the VERAFEYE™ navigation and imaging platform in order to achieve market approval and prepare for market entry.
Managed from the development office in Munich and the headquarters in Dublin, LUMA Vision has the potential to bring about global progress in the treatment of heart diseases associated with an ageing society
Monika Steger, Managing Director of Bayern Kapital.
Cardiac arrhythmias such as atrial fibrillation affect over 43 million people worldwide and are linked to strokes and other heart diseases. Treating these conditions is challenging, especially when it comes to heart surgery. LUMA Vision, a German-Irish medical technology company based in Dublin and Munich, is developing VERAFEYE™ technology to enable improved imaging and navigation during such procedures.
Together with the European Investment Bank, we have set up the Bavarian Growth Fund 2 precisely for companies like LUMA Vision. Bavaria needs many start-ups in the healthcare sector to strengthen the business location.
Hubert Aiwanger, Bavarian Minister of Economic Affairs
Bayern Kapital, as one of the new investors in this round, is continuing its support for innovative technologies in the healthcare sector. The venture/growth capital company of the Free State of Bavaria has already invested significant funds in numerous start-ups and scale-ups to drive innovative solutions.
The VERAFEYE™ platform is designed to provide cardiologists with accurate real-time data during interventional procedures to guide therapy more precisely. The technology combines a specialized catheter sensor with advanced imaging to generate high-resolution 360-degree images of the heart and its surroundings. This precise anatomical data should help doctors to carry out therapies more successfully and provide patients with improved treatment.
LUMA Vision was founded in 2017 by CTO Christoph Hennersperger and CEO Fionn Lahart and has offices in Dublin and Munich, where the development of the platform takes place.
FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
